

Specialist Advisory Committees

Objective advice to Pharmac

www.pharmac.govt.nz

Cancer Treatments Advisory Committee Provisional recommendations 25 June 2026

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.

[More information about provisional recommendations is on Pharmac's website](#)

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Trabectedin for the treatment of first line treatment of leiomyosarcoma, unresectable or metastatic, within the context of treatments for malignancy, subject to Special Authority criteria	High priority
Trabectedin for the treatment of second line treatment of liposarcoma or leiomyosarcoma, unresectable or metastatic, within the context of treatments for malignancy, subject to Special Authority criteria	Low priority
Eribulin for the treatment of advanced liposarcoma (following chemotherapy), within the context of treatments for malignancy, subject to Special Authority criteria	*Withheld
Ruxolitinib for the treatment of polycythaemia vera, intolerant or resistant to hydroxycarbamide (hydroxyurea), within the context of treatments for malignancy, subject to Special Authority criteria	Medium priority

*Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until full record is available.

[More information about the agenda items considered at the recent Cancer Treatments Advisory Committee meeting can be found on the Pharmac website.](#)

Released 17 July 2026